[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cuebiopharma” connections=”true” suffix=””]

Cue biologics are being designed to achieve a high level of specificity through the fusion of engineered T cell costimulatory signaling molecules (ligands) with a T cell receptor targeting complex (peptide-MHC) on a traditional antibody scaffold. The peptide interacts with disease-relevant T cells and the biologic delivers one of Cues engineered signaling ligands, thereby enabling exclusive modulation of the T cell population of interest